Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Langer

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysisC J Langer, J C Leighton, R L Comis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2012
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerM A Socinski, C J Langer, I Okamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2012
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumabH A Wakelee, S E Dahlberg, J R Brahmer, et al.
Seminars in Oncology|August 1, 1995
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experienceC J Langer, J C Leighton, R L Comis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II studyM H Jagasia, C J Langer, D H Johnson, et al.
British Journal of Cancer|November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabA Gualberto, M L Hixon, D D Karp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignanciesG R Hudes, C E Szarka, A Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysisC J Langer, J C Leighton, R L Comis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2012
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerM A Socinski, C J Langer, I Okamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|January 24, 2012
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumabH A Wakelee, S E Dahlberg, J R Brahmer, et al.
Seminars in Oncology|August 1, 1995
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experienceC J Langer, J C Leighton, R L Comis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II studyM H Jagasia, C J Langer, D H Johnson, et al.
British Journal of Cancer|November 25, 2010
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabA Gualberto, M L Hixon, D D Karp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignanciesG R Hudes, C E Szarka, A Adams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Pageof 5